[ { "Gosset drug_id": "67c0da8fe3d4a4c46883459f", "Asset": "PD-29875", "Developer group": "PeptiDream", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "PeptiDream", "Modality": "Peptides", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67c1af9dd5adeadf28e3bd89", "Asset": "68Ga-PMD22", "Developer group": "Peking Union Medical College Hospital", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Peking Union Medical College Hospital", "Modality": "Nanobodies (VHH); Beta Emitters; Alpha Emitters", "Lead indication": "Gastrointestinal cancer (CLDN18.2-positive tumors)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f6aa6a3623f1d2313f6347", "Asset": "Zolbetuximab / VYLOY", "Developer group": "Astellas", "Chart phase": "Approved", "Gosset phase": "Approved", "Gosset maintenance status": "Approved", "Developer / rights": "Astellas", "Modality": "Antibody", "Lead indication": "Locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma that is CLDN18.2-positive", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "FDA approved; first-line HER2-negative, CLDN18.2-positive advanced gastric/GEJ cancer with chemotherapy", "Development context": "Commercial reference; Phase 3 program adding pembrolizumab.", "Trial URLs": "https://clinicaltrials.gov/study/NCT03504397; https://clinicaltrials.gov/study/NCT03653507; https://clinicaltrials.gov/study/NCT06901531" }, { "Gosset drug_id": "67f6f91d9061c9a59242a45b", "Asset": "LNF-2007", "Developer group": "Lunan Pharmaceutical", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Lunan Pharmaceutical", "Modality": "Bispecific Antibodies", "Lead indication": "Advanced solid tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f70a8a9061c9a59242ac8d", "Asset": "XKDCT225", "Developer group": "Shenzhen Celconta Life Science", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Shenzhen Celconta Life Science", "Modality": "Gene Addition/Replacement; Vaccines & Immunotherapeutics; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f7ea269060f7552a054a0a", "Asset": "QLS31905", "Developer group": "Qilu", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Developer / rights": "Qilu", "Modality": "Bispecific", "Lead indication": "Claudin18.2-positive pancreatic ductal adenocarcinoma (advanced)", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Pancreatic Phase 3 recruiting; gastric Phase 3 not yet recruiting", "Development context": "CLDN18.2 x CD3; two first-line indication strategies. Do not label the gastric Phase 3 as recruiting.", "Trial URLs": "https://clinicaltrials.gov/study/NCT07079228; https://clinicaltrials.gov/study/NCT07716449" }, { "Gosset drug_id": "67f7ec5f9060f7552a054b2b", "Asset": "LB4330", "Developer group": "L&L Biopharma", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Active", "Developer / rights": "L&L Biopharma", "Modality": "Fc-Fusion Proteins", "Lead indication": "Pancreatic ductal adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f7f9ed9060f7552a055202", "Asset": "BL-M05D1", "Developer group": "Baili / SystImmune", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Developer / rights": "Sichuan Baili / SystImmune", "Modality": "ADC", "Lead indication": "Unresectable locally advanced or metastatic CLDN18.2-positive solid tumors", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 3 recruiting", "Development context": "Later-line gastric/GEJ ADC program; registry sponsor Sichuan Baili, Gosset lead SystImmune.", "Trial URLs": "https://clinicaltrials.gov/study/NCT07518147" }, { "Gosset drug_id": "67f804f94afab6023b2a958a", "Asset": "ASKB589", "Developer group": "AskGene", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Developer / rights": "AskGene", "Modality": "Antibody", "Lead indication": "CLDN18.2-positive, locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 3 active, not recruiting", "Development context": "First-line CAPOX plus PD-1 inhibitor combination; estimated primary completion Dec 2026.", "Trial URLs": "https://clinicaltrials.gov/study/NCT06206733" }, { "Gosset drug_id": "67f809194afab6023b2a999e", "Asset": "AK132", "Developer group": "Kangfang Sainuo Pharmaceutical", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Kangfang Sainuo Pharmaceutical", "Modality": "Bispecific Antibodies", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f814374afab6023b2aa4d4", "Asset": "TAC01-CLDN18.2", "Developer group": "Triumvira", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "Triumvira", "Modality": "Cell therapy", "Lead indication": "Claudin 18.2-positive gastric cancer", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 1/2 active, not recruiting; last update Feb 2025", "Development context": "T-cell antigen coupler (TAC) product. Kept distinct from conventional CAR-T despite broad Gosset classification.", "Trial URLs": "https://clinicaltrials.gov/study/NCT05862324" }, { "Gosset drug_id": "67f8159f4afab6023b2aa681", "Asset": "RC118", "Developer group": "RemeGen", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "RemeGen", "Modality": "ADC", "Lead indication": "Gastric cancer (including gastroesophageal junction cancer), Claudin 18.2-positive, locally advanced unresectable or metastatic", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 1/2 recruiting in registry; updates dated Jan 2025", "Development context": "MMAE ADC; earlier clinical watchlist, with aged registry timelines.", "Trial URLs": "https://clinicaltrials.gov/study/NCT05205850; https://clinicaltrials.gov/study/NCT06038396" }, { "Gosset drug_id": "67f817404afab6023b2aa869", "Asset": "BIO-008", "Developer group": "Yiling Pharmaceutical", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Yiling Pharmaceutical", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f818354afab6023b2aa989", "Asset": "TQB2103", "Developer group": "Sino Biopharmaceutical", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Sino Biopharmaceutical", "Modality": "Small Molecules; Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f81b394afab6023b2aace5", "Asset": "SG1906", "Developer group": "Hangzhou Sumgen Biotech", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Hangzhou Sumgen Biotech", "Modality": "Vaccines & Immunotherapeutics; Bispecific Antibodies", "Lead indication": "CLDN18.2-positive locally advanced unresectable or metastatic gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f820d94afab6023b2ab30a", "Asset": "ATG-022", "Developer group": "Antengene", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Developer / rights": "Antengene", "Modality": "ADC", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 3 registered, not yet recruiting", "Development context": "MMAE ADC; Phase 3 listing updated 31 Aug 2026. Clinical Phase 1/2 program exists.", "Trial URLs": "https://clinicaltrials.gov/study/NCT07795346" }, { "Gosset drug_id": "67f8fdd6f079deded4920efe", "Asset": "PM1032", "Developer group": "BioNTech", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "BioNTech", "Modality": "Bispecific Antibodies", "Lead indication": "CLDN18.2-positive gastrointestinal cancers (advanced or metastatic)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f90166f079deded49212ad", "Asset": "ASP2138", "Developer group": "Astellas", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Developer / rights": "Astellas", "Modality": "Bispecific", "Lead indication": "CLDN18.2-positive metastatic or locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 3 recruiting; first patient dosed Aug 2026", "Development context": "CLDN18.2 x CD3; subcutaneous administration; first-line pembrolizumab/chemotherapy combination.", "Trial URLs": "https://clinicaltrials.gov/study/NCT07673887" }, { "Gosset drug_id": "67f9039df079deded49214ff", "Asset": "DR30303", "Developer group": "Doer Bio", "Chart phase": "Discontinued", "Gosset phase": "Discontinued", "Gosset maintenance status": "Discontinued", "Developer / rights": "Doer Bio", "Modality": "Nanobodies (VHH); Cytotoxic ADCs; Monoclonal Antibodies; Fc-Fusion Proteins", "Lead indication": "Claudin18.2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f907bbf079deded4921932", "Asset": "NBL-015", "Developer group": "NovaRock Biotherapeutics", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "NovaRock Biotherapeutics", "Modality": "Monoclonal Antibodies; Recombinant Proteins and Enzymes", "Lead indication": "Gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f907faf079deded4921972", "Asset": "SOT102", "Developer group": "SOTIO", "Chart phase": "Discontinued", "Gosset phase": "2", "Gosset maintenance status": "Active", "Developer / rights": "SOTIO", "Modality": "ADC", "Lead indication": "Advanced or metastatic pancreatic adenocarcinoma (CLDN18.2 positive)", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Clinical development discontinued; trial terminated", "Development context": "Overrides Gosset Active label; sponsor-authored paper reports unexpected toxicities and discontinued development.", "Trial URLs": "https://clinicaltrials.gov/study/NCT05525286" }, { "Gosset drug_id": "67f90d31f079deded4921e7e", "Asset": "TORL-2-307-ADC", "Developer group": "TORL BioTherapeutics", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "TORL BioTherapeutics", "Modality": "Recombinant Proteins and Enzymes; Cytotoxic ADCs", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f91027a8a467cb7b3fb755", "Asset": "TORL-2-307-MAB", "Developer group": "TORL BioTherapeutics", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "TORL BioTherapeutics", "Modality": "Classical Binding Small Molecules; Recombinant Proteins and Enzymes; Covalent Small Molecules; Vaccines & Immunotherapeutics; Monoclonal Antibodies; Nucleic Acid-Directed Small Molecules", "Lead indication": "Advanced gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f9103fa8a467cb7b3fb76f", "Asset": "ZL-1211", "Developer group": "Zai Lab", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Active", "Developer / rights": "Zai Lab", "Modality": "Monoclonal Antibodies", "Lead indication": "Claudin 18.2-positive unresectable or metastatic gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f9104fa8a467cb7b3fb780", "Asset": "BNT141", "Developer group": "BioNTech", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "BioNTech", "Modality": "Lipid-based Nanoparticles; mRNA Therapeutics", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f913c3a8a467cb7b3fbafd", "Asset": "IBI345", "Developer group": "Innovent", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Innovent Biologics", "Modality": "CAR-T Cells", "Lead indication": "Advanced Claudin18.2-positive solid tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f91873a8a467cb7b3fbf91", "Asset": "IBI-360", "Developer group": "Suzhou Innovent Biologics", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Suzhou Innovent Biologics", "Modality": "Monoclonal Antibodies; Vaccines & Immunotherapeutics", "Lead indication": "Unresectable, locally advanced or metastatic solid tumors expressing Claudin 18.2", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f91aa2a8a467cb7b3fc185", "Asset": "tecotabart", "Developer group": "LaNova", "Chart phase": "Discontinued", "Gosset phase": "Discontinued", "Gosset maintenance status": "Discontinued", "Developer / rights": "LaNova Medicines", "Modality": "Monoclonal Antibodies", "Lead indication": "CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f91cb8a8a467cb7b3fc377", "Asset": "EO-3021 / SYSA1801", "Developer group": "Elevation / CSPC (territory-specific history)", "Chart phase": "Discontinued", "Gosset phase": "Discontinued", "Gosset maintenance status": "Discontinued", "Developer / rights": "Elevation / CSPC (territory-specific history)", "Modality": "ADC", "Lead indication": "Claudin 18.2-positive gastric cancer and gastroesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Elevation program discontinued; global territory status not established", "Development context": "Elevation discontinuation must not automatically be generalized to all CSPC territories. Chinese Phase 1 registry remains Unknown and old.", "Trial URLs": "https://clinicaltrials.gov/study/NCT05980416; https://clinicaltrials.gov/study/NCT05009966" }, { "Gosset drug_id": "67f9251aa8a467cb7b3fcb15", "Asset": "Givastomig / ABL111", "Developer group": "NovaBridge / ABL Bio", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "NovaBridge / ABL Bio", "Modality": "Bispecific", "Lead indication": "HER2-negative, CLDN18.2-positive, PD-L1-positive locally advanced unresectable or metastatic gastroesophageal adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Randomized Phase 2 recruiting; Phase 3 planned, not established as started", "Development context": "CLDN18.2 x 4-1BB; first-line immunochemotherapy; low-expression eligibility. Sponsor aims for Phase 3 as early as year-end 2026.", "Trial URLs": "https://clinicaltrials.gov/study/NCT07432295; https://clinicaltrials.gov/study/NCT04900818" }, { "Gosset drug_id": "67f9266da8a467cb7b3fcc63", "Asset": "FG-M108 / M108", "Developer group": "FutureGen", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Developer / rights": "FutureGen (registry sponsor)", "Modality": "Antibody", "Lead indication": "CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Gastric Phase 3 recruiting; pancreatic Phase 3 not yet recruiting", "Development context": "Gastric trial selects HER2-negative, PD-L1 CPS<5 disease and compares M108 plus CAPOX with placebo plus CAPOX. Gastric registry last updated Feb 2024.", "Trial URLs": "https://clinicaltrials.gov/study/NCT06177041; https://clinicaltrials.gov/study/NCT07383922" }, { "Gosset drug_id": "67f928b4a8a467cb7b3fcea3", "Asset": "q-1802", "Developer group": "QureBio", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "QureBio", "Modality": "Bispecific Antibodies", "Lead indication": "CLDN18.2-positive, HER2-negative unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f92b75a8a467cb7b3fd13c", "Asset": "MIL93", "Developer group": "Mabworks Biotech", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Mabworks Biotech", "Modality": "Monoclonal Antibodies; Recombinant Proteins and Enzymes", "Lead indication": "Gastric cancer (CLDN18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f94687a8a467cb7b3fea3f", "Asset": "gresonitamab", "Developer group": "Amgen", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Amgen", "Modality": "Bispecific Antibodies", "Lead indication": "CLDN18.2-positive gastric and gastroesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f94849a8a467cb7b3febe1", "Asset": "ab011", "Developer group": "CARsgen", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "CARsgen Therapeutics", "Modality": "Monoclonal Antibodies", "Lead indication": "Gastrooesophageal junction cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f96b4ea8a467cb7b400be7", "Asset": "AZD6422", "Developer group": "AstraZeneca", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Active", "Developer / rights": "AstraZeneca", "Modality": "Autologous CAR-T", "Lead indication": "Gastric cancer (CLDN18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f97521a8a467cb7b4014bf", "Asset": "CT-048", "Developer group": "CARsgen", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "CARsgen Therapeutics", "Modality": "Autologous CAR-T", "Lead indication": "Advanced gastric or gastroesophageal junction adenocarcinoma, CLDN18.2-positive", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "67f994d6a8a467cb7b402bef", "Asset": "LCAR-C182A", "Developer group": "Nanjing Legend Biotech", "Chart phase": "Discontinued", "Gosset phase": "Discontinued", "Gosset maintenance status": "Discontinued", "Developer / rights": "Nanjing Legend Biotech", "Modality": "Gene Addition/Replacement; Vaccines & Immunotherapeutics; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Advanced Gastric Carcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "68038f72e845f2ae11fe0b93", "Asset": "ALLO-182", "Developer group": "Allogene Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Allogene Therapeutics", "Modality": "CAR-T Cells", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "68038fc9e845f2ae11fe0dd6", "Asset": "BDC-4182", "Developer group": "Bolt Biotherapeutics", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "Bolt Biotherapeutics", "Modality": "Small Molecules; Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Metastatic gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "68039060e845f2ae11fe11ca", "Asset": "IMC008", "Developer group": "Immunofoco", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Immunofoco", "Modality": "CAR-T Cells", "Lead indication": "Advanced solid tumors with CLDN18.2 expression", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "68039091e845f2ae11fe12fc", "Asset": "LY011", "Developer group": "Shanghai Longyao Biotechnology", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Shanghai Longyao Biotechnology", "Modality": "CAR-T Cells", "Lead indication": "Advanced gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "680390cfe845f2ae11fe147c", "Asset": "OriC613", "Developer group": "OriCell Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "OriCell Therapeutics", "Modality": "CAR-T Cells", "Lead indication": "Mesothelin-expressing malignant pleural mesothelioma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "680390dde845f2ae11fe14d6", "Asset": "Spevatamig / PT886", "Developer group": "Phanes", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "Phanes", "Modality": "Bispecific", "Lead indication": "Advanced gastric carcinoma (including gastroesophageal junction adenocarcinoma)", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 1/2 recruiting", "Development context": "CLDN18.2 x CD47; differentiates through macrophage checkpoint biology.", "Trial URLs": "https://clinicaltrials.gov/study/NCT05482893" }, { "Gosset drug_id": "68039146e845f2ae11fe177a", "Asset": "TORL-2-307", "Developer group": "TORL BioTherapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "TORL BioTherapeutics", "Modality": "Recombinant Proteins and Enzymes; Cytotoxic ADCs; Small Molecules; Monoclonal Antibodies", "Lead indication": "Gastric cancer (Claudin 18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "680391f2e845f2ae11fe1bdb", "Asset": "ALA-105", "Developer group": "Arovella Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Arovella Therapeutics", "Modality": "Classical Binding Small Molecules; Covalent Small Molecules; Gene Addition/Replacement; Vaccines & Immunotherapeutics; CAR-T Cells; Nucleic Acid-Directed Small Molecules; Gene Silencing; Gene Editing", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "682e5859a83c5cea4839612d", "Asset": "JS107", "Developer group": "Junshi", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Active", "Developer / rights": "Junshi", "Modality": "ADC", "Lead indication": "CLDN18.2-positive gastric (stomach) adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Two Phase 3 trials recruiting", "Development context": "MMAE ADC; later-line monotherapy and first-line toripalimab/chemotherapy regimens.", "Trial URLs": "https://clinicaltrials.gov/study/NCT07284134; https://clinicaltrials.gov/study/NCT07584135" }, { "Gosset drug_id": "682e59bca83c5cea48396532", "Asset": "Claudin18.2 CAR-T cells", "Developer group": "CARsgen", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "CARsgen Therapeutics", "Modality": "CAR-T Cells", "Lead indication": "Gastric/gastroesophageal junction cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "682e5c26a83c5cea48396c50", "Asset": "JS012", "Developer group": "Junshi", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Junshi Biosciences", "Modality": "Monoclonal Antibodies", "Lead indication": "Resistant or refractory CLDN18.2-expressing solid tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6833c83f67141c9b36be4c51", "Asset": "IBI343 / TAK-921 (arcotatug tavatecan)", "Developer group": "Innovent", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Developer / rights": "Innovent; Takeda outside Greater China", "Modality": "ADC", "Lead indication": "Advanced gastric/gastroesophageal junction adenocarcinoma (CLDN18.2-positive)", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "China NDA accepted; positive Phase 3 interim analysis announced 4 Jun 2026", "Development context": "TOP1-payload ADC; later-line gastric filing and Phase 3 pancreatic expansion. Full comparative data remain important.", "Trial URLs": "https://clinicaltrials.gov/study/NCT06238843; https://clinicaltrials.gov/study/NCT07066098" }, { "Gosset drug_id": "6850242096570406a881bf9f", "Asset": "CLDN18.2 UCAR-T", "Developer group": "Suzhou Maximum Bio-tech", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Suzhou Maximum Bio-tech", "Modality": "CAR-T Cells", "Lead indication": "Gastric cancer (advanced, CLDN18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "68504ef06d7a673187a4d391", "Asset": "RD07 cell injection", "Developer group": "Not recorded", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Not recorded", "Modality": "Cell Therapies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6850d21da9de34c67faf6178", "Asset": "IMPT-601", "Developer group": "Lyell Immunopharma", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Lyell Immunopharma", "Modality": "CAR-T Cells", "Lead indication": "Gastric cancer (including gastroesophageal junction cancer, GC/GEJC)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6850fe62a9de34c67faf6685", "Asset": "HBM7022", "Developer group": "AstraZeneca", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "AstraZeneca", "Modality": "Bispecific Antibodies", "Lead indication": "Advanced gastric carcinoma (Claudin 18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "68595ec7249a3aeb5dcca406", "Asset": "TAC-T cell", "Developer group": "Triumvira", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Triumvira Immunologics", "Modality": "TCR-Engineered T Cells; Gene Addition/Replacement; Gene Silencing; Gene Editing", "Lead indication": "HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6866e47a19ccbd38c89f1d09", "Asset": "SIBP-A18", "Developer group": "Shanghai Institute of Biological Products", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Shanghai Institute of Biological Products", "Modality": "Cytotoxic ADCs", "Lead indication": "Claudin 18.2-positive late-stage gastric cancer/gastroesophageal junction cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6866e5e919ccbd38c89f1f34", "Asset": "AZD4360", "Developer group": "AstraZeneca", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "AstraZeneca", "Modality": "Cytotoxic ADCs", "Lead indication": "Gastric or Gastroesophageal Junction Cancer, CLDN18.2-positive, advanced or metastatic", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6866e63919ccbd38c89f1fab", "Asset": "Claudin18.2-targeted Chimeric Antigen Receptor Dendritic Cells", "Developer group": "Second Affiliated Hospital of Zhejiang University School of Medicine", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Second Affiliated Hospital of Zhejiang University School of Medicine", "Modality": "Dendritic Cell Vaccines", "Lead indication": "Advanced colorectal cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6866e74919ccbd38c89f20ea", "Asset": "BA1301", "Developer group": "Boan Biotech", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Boan Biotech", "Modality": "Cytotoxic ADCs", "Lead indication": "Advanced gastric cancer (Claudin 18.2-expressing)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "688f82dd08cd9f55210300ad", "Asset": "CAR-iNKT cells", "Developer group": "Arovella Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Arovella Therapeutics", "Modality": "CAR-T Cells; CAR-NK Cells; Lymphokine-Activated Killer Cells", "Lead indication": "Relapsed/refractory/high-risk CD19-positive B-cell lymphoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "689755c6ccd55fd695466e05", "Asset": "CAR-CLDN18.2", "Developer group": "CARsgen", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "CARsgen Therapeutics", "Modality": "CAR-T Cells", "Lead indication": "Advanced gastric cancer, CLDN18.2-positive", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "68cbf5a53b71859dcd59d7c9", "Asset": "Sonesitatug vedotin / AZD0901 / CMG901", "Developer group": "AstraZeneca", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Active", "Developer / rights": "AstraZeneca", "Modality": "ADC", "Lead indication": "Advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, Claudin18.2-positive, HER2-negative", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 3 positive OS topline; no approval established in reviewed sources", "Development context": "MMAE ADC; 3L+ OS primary and 2L+ OS secondary endpoints met; 2L+ PFS primary not significant. First-line Phase 3 also recruiting.", "Trial URLs": "https://clinicaltrials.gov/study/NCT06346392; https://clinicaltrials.gov/study/NCT07431281" }, { "Gosset drug_id": "68cc48c7d1b9e2725213eaa7", "Asset": "Satri-cel / CT041", "Developer group": "CARsgen", "Chart phase": "Approved", "Gosset phase": "2", "Gosset maintenance status": "Active", "Developer / rights": "CARsgen", "Modality": "Cell therapy", "Lead indication": "Claudin18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "China approved 22 Jun 2026; HER2-negative, CLDN18.2-positive advanced gastric/GEJ cancer after at least two prior lines", "Development context": "Regional approval overrides raw Phase 2 classification; pancreatic adjuvant expansion remains investigational.", "Trial URLs": "https://clinicaltrials.gov/study/NCT04581473; https://clinicaltrials.gov/study/NCT05911217" }, { "Gosset drug_id": "68cc48d0d1b9e2725213eaaa", "Asset": "Osemitamab / TST001", "Developer group": "Transcenta", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Developer / rights": "Transcenta", "Modality": "Antibody", "Lead indication": "HER2-negative, CLDN18.2-expressing gastric or gastroesophageal junction adenocarcinoma, locally advanced or metastatic", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 3 registered, not yet recruiting; clinical evidence from earlier phases", "Development context": "Enhanced-effector antibody; planned first-line pembrolizumab/chemotherapy study. Registration is not evidence that Phase 3 dosing began.", "Trial URLs": "https://clinicaltrials.gov/study/NCT06093425" }, { "Gosset drug_id": "68cd525180f6166b24a8eece", "Asset": "LM-302 (tecotabart vedotin; TPX-4589)", "Developer group": "LaNova", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Active", "Developer / rights": "LaNova / Sino Biopharmaceutical", "Modality": "ADC", "Lead indication": "CLDN18.2-positive gastric and gastroesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "China NDA accepted; positive pivotal interim analysis announced 23 Jun 2026", "Development context": "MMAE ADC; both pivotal endpoints reported met; detailed results planned early 2027. Current sponsor replaces historical BMS attribution.", "Trial URLs": "https://clinicaltrials.gov/study/NCT06351020; https://clinicaltrials.gov/study/NCT07385703" }, { "Gosset drug_id": "68de720118e2ea74a47a6902", "Asset": "FL-302", "Developer group": "Leap Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Leap Therapeutics", "Modality": "Bispecific Antibodies", "Lead indication": "Gastric adenocarcinoma (including gastroesophageal junction adenocarcinoma) expressing Claudin 18.2", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "68f38cee2b7dd5c5e3648e04", "Asset": "99mTc-PHG102", "Developer group": "Not recorded", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Not recorded", "Modality": "Nanobodies (VHH); Beta Emitters; Alpha Emitters", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "693c2b7f915f829e97e4d519", "Asset": "Claudin18.2 mRNA cancer vaccine", "Developer group": "Moderna", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Moderna", "Modality": "Vaccines & Immunotherapeutics; mRNA Therapeutics", "Lead indication": "Gastric cancer (including gastroesophageal junction adenocarcinoma)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "693ca876915f829e97e4e09d", "Asset": "YH005", "Developer group": "RemeGen", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "RemeGen", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "693eb64ded1d4f34cbe375f6", "Asset": "HBM1029", "Developer group": "Harbour BioMed", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Harbour BioMed", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "693f5636d91942c1924b6507", "Asset": "SHR-A1904 (garetatug rezetecan)", "Developer group": "Hengrui", "Chart phase": "3", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Developer / rights": "Hengrui", "Modality": "ADC", "Lead indication": "Gastric or gastroesophageal junction adenocarcinoma, CLDN18.2-positive, advanced", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 3 recruiting", "Development context": "TOP1 ADC; second-line gastric/GEJ trial versus chemotherapy; China sites in registry.", "Trial URLs": "https://clinicaltrials.gov/study/NCT06649292" }, { "Gosset drug_id": "69548666458f3b4e38613058", "Asset": "GC506", "Developer group": "Gracell Biotechnologies", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Gracell Biotechnologies", "Modality": "CAR-T Cells", "Lead indication": "Claudin 18.2-positive gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6954cf3903b36ebed5e8ba34", "Asset": "[68Ga]Ga-NOTA-3A12", "Developer group": "Fudan University", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Fudan University", "Modality": "Nanobodies (VHH); Beta Emitters; Alpha Emitters", "Lead indication": "Not recorded", "Diagnostic flag": true, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6954dfc603b36ebed5e8bb7e", "Asset": "[18F]F-RESCA-3A12", "Developer group": "Not recorded", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Not recorded", "Modality": "Nanobodies (VHH); Beta Emitters; Alpha Emitters", "Lead indication": "Gastric cancer", "Diagnostic flag": true, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6959730aaabfaff2edb0b817", "Asset": "IM92", "Developer group": "Immunochina Pharmaceuticals", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Immunochina Pharmaceuticals", "Modality": "Gene Addition/Replacement; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Gastric adenocarcinoma (unresectable, locally advanced, or metastatic)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6964eb6f44744dde90c12a66", "Asset": "SmarT (Senlang Bio)", "Developer group": "Senlang Bio", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Senlang Bio", "Modality": "CAR-T Cells", "Lead indication": "Gastric cancer (advanced, CLDN18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6969227c9b3ababd48ef9326", "Asset": "CTB001", "Developer group": "Bioheng Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Bioheng Therapeutics", "Modality": "CAR-T Cells", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6981a9534c42f65bc417ca97", "Asset": "89Zr-DFO-zolbetuximab", "Developer group": "Massachusetts General Hospital", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Massachusetts General Hospital", "Modality": "Beta Emitters; Alpha Emitters; Monoclonal Antibodies", "Lead indication": "Gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6981a96c4c42f65bc417ca99", "Asset": "177Lu-DOTA-zolbetuximab", "Developer group": "Massachusetts General Hospital", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Massachusetts General Hospital", "Modality": "Beta Emitters; Alpha Emitters; Monoclonal Antibodies", "Lead indication": "CLDN18.2-positive gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69838a8c1d89c70aa6ee5aa3", "Asset": "QLS5316", "Developer group": "Qilu", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Qilu Pharmaceutical", "Modality": "Monoclonal Antibodies; Bispecific Antibodies", "Lead indication": "Advanced Solid Tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "698ff3a891d3c222f76b1161", "Asset": "BG2103", "Developer group": "Guangzhou Bio-gene Technology", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Guangzhou Bio-gene Technology", "Modality": "CAR-T Cells", "Lead indication": "Malignant gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "698ff92191d3c222f76b125b", "Asset": "IMC004", "Developer group": "Immunofoco", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Immunofoco", "Modality": "CAR-T Cells", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "698ff92f91d3c222f76b125e", "Asset": "IMV103", "Developer group": "Immunofoco", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Immunofoco", "Modality": "Gene Addition/Replacement; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69902b6a91d3c222f76b1b63", "Asset": "AT-211", "Developer group": "AbTis", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "AbTis", "Modality": "Immunomodulatory ADCs; Cytotoxic ADCs", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6990432191d3c222f76b1ff2", "Asset": "BC008", "Developer group": "Dragonboat Biopharmaceutical", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Dragonboat Biopharmaceutical", "Modality": "Monoclonal Antibodies; Fc-Fusion Proteins", "Lead indication": "CLDN18.2-positive advanced malignant solid tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6990433191d3c222f76b1ff5", "Asset": "BC007", "Developer group": "Dragonboat Biopharmaceutical", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Dragonboat Biopharmaceutical", "Modality": "Bispecific Antibodies", "Lead indication": "Advanced solid tumors expressing CLDN18.2", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6990434691d3c222f76b1ff9", "Asset": "ABP-150", "Developer group": "Abpro", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Abpro", "Modality": "Bispecific Antibodies", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6991cead7371cbf1011cfaf9", "Asset": "BPI-9304A", "Developer group": "Beta Pharma", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Beta Pharma", "Modality": "Cytotoxic ADCs", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6991dcdf7371cbf1011cfdb2", "Asset": "Claudin 18.2-targeted U-CART", "Developer group": "Legend Biotech", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Legend Biotech", "Modality": "CAR-T Cells", "Lead indication": "Unresectable, locally advanced, or metastatic gastric adenocarcinoma (including gastroesophageal junction and esophageal adenocarcinoma)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6991fa167371cbf1011d039f", "Asset": "JS307", "Developer group": "Top Alliance Biosciences", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Top Alliance Biosciences", "Modality": "Cytotoxic ADCs", "Lead indication": "Advanced CLDN18.2-high gastric or gastro-oesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "699210467371cbf1011d0801", "Asset": "64Cu-PD-29875", "Developer group": "PeptiDream", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "PeptiDream", "Modality": "Beta Emitters; Alpha Emitters; Peptides", "Lead indication": "Gastric cancer (including esophagogastric junction cancer)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69a8af003fc547c70d82a7b9", "Asset": "ANO31905", "Developer group": "Anova Evidence", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "Anova Evidence", "Modality": "Monoclonal Antibodies", "Lead indication": "CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b211761dc90a39311bfe02", "Asset": "DP-388", "Developer group": "D&P Bio-tX", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "D&P Bio-tX", "Modality": "Monoclonal Antibodies; Bispecific Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b388281dc90a39311c2233", "Asset": "YT-1006", "Developer group": "Shanghai Yitai Pharmaceutical", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Shanghai Yitai Pharmaceutical", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b8062c43997a3a9091c70c", "Asset": "LCB02A", "Developer group": "LigaChem Biosciences, Inc.", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "LigaChem Biosciences, Inc.", "Modality": "Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Gastric cancer (CLDN18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b8068c43997a3a9091c71f", "Asset": "SKB103", "Developer group": "Kelun-Biotech", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "Kelun-Biotech", "Modality": "Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b81d5a43997a3a9091cbc7", "Asset": "Claudin18.2 Targeted Activated Dendritic Cells", "Developer group": "Hainan Cancer Hospital", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Hainan Cancer Hospital", "Modality": "Dendritic Cell Vaccines", "Lead indication": "Advanced pancreatic cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b81d6643997a3a9091cbc9", "Asset": "claudin18.2-targeted CAR-T cells", "Developer group": "Hainan Cancer Hospital", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Hainan Cancer Hospital", "Modality": "CAR-T Cells", "Lead indication": "Advanced pancreatic cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b81ea443997a3a9091cc11", "Asset": "HWS116", "Developer group": "Wuhan Humanwell Innovative Drug Research and Development Center", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Wuhan Humanwell Innovative Drug Research and Development Center", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b827b443997a3a9091cdfe", "Asset": "CBG131", "Developer group": "The First Affiliated Hospital of Wenzhou Medical University", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "The First Affiliated Hospital of Wenzhou Medical University", "Modality": "Gene Addition/Replacement; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Advanced gastric or gastroesophageal junction adenocarcinoma (CLDN18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b8843122fa813c0ff361b8", "Asset": "claudin 18.2 CAR-T cells (Essen Biotech)", "Developer group": "CARsgen", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "CARsgen Therapeutics", "Modality": "CAR-T Cells", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b8c26122fa813c0ff3b105", "Asset": "XKDCT086", "Developer group": "The Affiliated Hospital of Qingdao University", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "The Affiliated Hospital of Qingdao University", "Modality": "Gene Addition/Replacement; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Gastric cancer (Claudin18.2-positive, advanced/recurrent/refractory)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b8d6a822fa813c0ff3c861", "Asset": "Claudin18.2 CAR-T cells (Shenzhen University General Hospital)", "Developer group": "Shenzhen Haoshi Biotechnology", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Shenzhen Haoshi Biotechnology", "Modality": "Gene Addition/Replacement; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Advanced pancreatic adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b8e1b022fa813c0ff3d552", "Asset": "68Ga-ACN376", "Developer group": "Peking University Cancer Hospital & Institute", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Peking University Cancer Hospital & Institute", "Modality": "Nanobodies (VHH); Beta Emitters; Alpha Emitters", "Lead indication": "CLDN18.2-positive solid tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69b9242422fa813c0ff41bec", "Asset": "LCAR-C18S", "Developer group": "Legend Biotech", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Legend Biotech", "Modality": "Gene Addition/Replacement; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69ba4fb51aa84c922c91034a", "Asset": "ZW439", "Developer group": "Zymeworks", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Zymeworks", "Modality": "Cytotoxic ADCs", "Lead indication": "Pancreatic cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69ba50081aa84c922c910359", "Asset": "XTX601", "Developer group": "Xilio Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Xilio Therapeutics", "Modality": "T-cell Engagers; Bispecific Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69bee8ca96eddacffe55a4ab", "Asset": "DA-3501", "Developer group": "Dong-A ST", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Dong-A ST", "Modality": "Cytotoxic ADCs", "Lead indication": "Gastric cancer (Claudin 18.2-positive, advanced)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69bee8d196eddacffe55a4be", "Asset": "EB-DNK102", "Developer group": "Beijing Biotech", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "Beijing Biotech", "Modality": "CAR-NK Cells; Lymphokine-Activated Killer Cells", "Lead indication": "Advanced Pancreatic Ductal Adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69c21a6a3ffc807a78bd668a", "Asset": "fuzituximab", "Developer group": "Astellas", "Chart phase": "Discontinued", "Gosset phase": "Discontinued", "Gosset maintenance status": "Discontinued", "Developer / rights": "Astellas Pharma", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69c34068774377403427d952", "Asset": "ASP546C / XNW27011", "Developer group": "Astellas", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "Astellas / Evopoint", "Modality": "ADC", "Lead indication": "Gastroesophageal adenocarcinoma (including gastric and gastroesophageal junction [GEJ] cancer), CLDN18.2-expressing, locally advanced unresectable or metastatic", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Phase 1/2 recruiting", "Development context": "TOP1 ADC; ex-Greater-China rights licensed to Astellas.", "Trial URLs": "https://clinicaltrials.gov/study/NCT07488676; https://clinicaltrials.gov/study/NCT06792435" }, { "Gosset drug_id": "69ccfffd3850797ed1634cc8", "Asset": "LY011 (Shanghai Longyao Biotechnology Co., Ltd.)", "Developer group": "Shanghai Longyao Biotechnology", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Shanghai Longyao Biotechnology", "Modality": "Cell Therapies", "Lead indication": "Advanced gastric adenocarcinoma (CLDN18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69cdec1164ec70f5499b3e82", "Asset": "KJ-C2527 (Kaixing Life Technology (Shanghai) Co., Ltd.)", "Developer group": "CARsgen", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "CARsgen Therapeutics", "Modality": "CAR-T Cells", "Lead indication": "CLDN18.2-positive Stomach Cancer (gastric cancer)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d1230587d7c2063ea41952", "Asset": "TRAB360", "Developer group": "Transcenta", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Transcenta", "Modality": "T-cell Engagers; Bispecific Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d1520e6f9c6d501576cab1", "Asset": "KD-055", "Developer group": "Nanjing KAEDI Biotech", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Nanjing KAEDI Biotech", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d152236f9c6d501576cab7", "Asset": "KD-182", "Developer group": "Nanjing KAEDI Biotechnology", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Nanjing KAEDI Biotechnology", "Modality": "Gene Addition/Replacement; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d1dbf714c20794d630f29a", "Asset": "IBI-307", "Developer group": "Innovent", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Innovent Biologics", "Modality": "Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Gastric/gastroesophageal junction adenocarcinoma (advanced) expressing Claudin 18.2", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d46a63027af456cc592964", "Asset": "124I-18B10", "Developer group": "Peking University Cancer Hospital & Institute", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Peking University Cancer Hospital & Institute", "Modality": "Beta Emitters; Alpha Emitters; Monoclonal Antibodies", "Lead indication": "Claudin 18.2-positive gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d56de63ff5707fe5eeaa4a", "Asset": "claudin 18.2 targeted proapoptotic peptide", "Developer group": "Kyungpook National University", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Kyungpook National University", "Modality": "Peptide-Drug Conjugates", "Lead indication": "Pancreatic cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d62519027af456cc59c380", "Asset": "[89Zr]Zr-DFO-TST001", "Developer group": "Transcenta", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Transcenta", "Modality": "Beta Emitters; Alpha Emitters; Monoclonal Antibodies", "Lead indication": "Gastrointestinal tumors expressing Claudin 18.2", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d664b6e4cb0bb0fe4873ee", "Asset": "VHH-based Claudin 18.2 CAR T-cell", "Developer group": "Celest Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Celest Therapeutics", "Modality": "Nanobodies (VHH); CAR-T Cells", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d66b08e4cb0bb0fe4874eb", "Asset": "VTS208", "Developer group": "Virtuoso Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Virtuoso Therapeutics", "Modality": "T-cell Engagers; Trispecific Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d66c40e4cb0bb0fe487520", "Asset": "PC18.1", "Developer group": "Tianjin Medical University Cancer Institute and Hospital", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Tianjin Medical University Cancer Institute and Hospital", "Modality": "Peptides", "Lead indication": "Gastric or gastroesophageal junction adenocarcinoma (CLDN18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d67fabe4cb0bb0fe487770", "Asset": "armored CLDN18.2 nanobody CAR NK cells", "Developer group": "iCell Gene Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "iCell Gene Therapeutics", "Modality": "Nanobodies (VHH); CAR-NK Cells; Lymphokine-Activated Killer Cells", "Lead indication": "CLDN18.2-positive stomach cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d6f20518d51935befae168", "Asset": "CLDN18.2-BBZ", "Developer group": "OriCell Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "OriCell Therapeutics", "Modality": "CAR-T Cells", "Lead indication": "Advanced gastric cancer (stomach adenocarcinoma, STAD)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d6f53718d51935befae1e9", "Asset": "inducible Claudin18.2/FAP CAR-T", "Developer group": "Mayo Clinic", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Mayo Clinic", "Modality": "Nanobodies (VHH); CAR-T Cells", "Lead indication": "Advanced gastric or gastro-oesophageal junction (GOJ) adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d6f54018d51935befae1eb", "Asset": "hu8E85 CART", "Developer group": "CARsgen", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "CARsgen Therapeutics", "Modality": "CAR-T Cells", "Lead indication": "Unresectable, locally advanced, or metastatic gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d6f54b18d51935befae1ee", "Asset": "Claudin18.2-targeting CAR-T cells", "Developer group": "CARsgen", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "CARsgen Therapeutics", "Modality": "CAR-T Cells", "Lead indication": "Advanced gastric/gastroesophageal junction cancer, Claudin18.2-positive", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69d8124a192cac7c05718b1a", "Asset": "[177Lu]Lu-TST001", "Developer group": "Transcenta", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Transcenta", "Modality": "Beta Emitters; Alpha Emitters; Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69dad9e0df153048dc84277b", "Asset": "Multi-target CAR-T cells (Second Affiliated Hospital of Guangzhou Medical University)", "Developer group": "Second Affiliated Hospital of Guangzhou Medical University", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Second Affiliated Hospital of Guangzhou Medical University", "Modality": "Gene Editing; Gene Addition/Replacement; Gene Silencing; CAR-T Cells", "Lead indication": "Liver cancer (hepatocellular carcinoma, GPC3/Mesothelin-expressing)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69dadddadf153048dc8441a3", "Asset": "Claudin18.2-targeted CAR-T Cells (Second Affiliated Hospital, School of Medicine, Zhejiang University)", "Developer group": "Second Affiliated Hospital of Zhejiang University School of Medicine", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Second Affiliated Hospital of Zhejiang University School of Medicine", "Modality": "Gene Addition/Replacement; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Advanced colorectal adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69de51afdadfc14ce44c8503", "Asset": "CT048", "Developer group": "Peking University Cancer Hospital & Institute", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Peking University Cancer Hospital & Institute", "Modality": "CAR-T Cells", "Lead indication": "Advanced Gastric Cancer (Adenocarcinoma)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e27a1da855d1fa29e5dab7", "Asset": "CB CAR-NK182", "Developer group": "Hangzhou RonGu Biotechnology", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Active", "Developer / rights": "Hangzhou RonGu Biotechnology", "Modality": "CAR-NK Cells; Lymphokine-Activated Killer Cells", "Lead indication": "Advanced gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e43ff5cbc1285fe0df9d47", "Asset": "IASO209", "Developer group": "Reindeer Biotech", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Reindeer Biotech", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e441aecbc1285fe0dfa075", "Asset": "CLDN18.2 SIR-T", "Developer group": "Angeles Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Angeles Therapeutics", "Modality": "TCR-Engineered T Cells", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e4433acbc1285fe0dfa367", "Asset": "KeyGen-Claudin18.2 mAb/ADC", "Developer group": "Beijing KeyGen", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Beijing KeyGen", "Modality": "Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e44b94cbc1285fe0dfb41d", "Asset": "WP-CLDN18.2-CAR-T", "Developer group": "Waypoint Bio", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Waypoint Bio", "Modality": "CAR-T Cells", "Lead indication": "Gastric adenocarcinoma (unresectable, locally advanced or metastatic, CLDN18.2-positive)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e6efc5f5e80bfdc057e9eb", "Asset": "claudin 18.2 monoclonal antibody", "Developer group": "Vaccinex", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Vaccinex", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e7736184eb800a4518224c", "Asset": "ST114", "Developer group": "Hangzhou Ruiao Biopharmaceutical", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Hangzhou Ruiao Biopharmaceutical", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e7736884eb800a45182280", "Asset": "XCCS605B", "Developer group": "Shanghai Huayu Biotech", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Shanghai Huayu Biotech", "Modality": "Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e7737184eb800a451822cc", "Asset": "IBI3028", "Developer group": "Innovent", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Innovent Biologics", "Modality": "Monoclonal Antibodies; Bispecific Antibodies", "Lead indication": "Locally advanced, unresectable, or metastatic treatment-refractory solid tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e773a484eb800a45182476", "Asset": "SKB315 / MK-1200 (Gosset: lucansatuzumab)", "Developer group": "Kelun", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Active", "Developer / rights": "Kelun; historical Merck trial sponsor", "Modality": "ADC", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": true, "Status / review scope": "Kelun Phase 1 recruiting; Phase 2 registered, not yet recruiting; Merck Phase 1/2 completed", "Development context": "TOP1 ADC. Ownership/rights not inferred from a completed Merck trial; distinct regional trial statuses retained.", "Trial URLs": "https://clinicaltrials.gov/study/NCT05367635; https://clinicaltrials.gov/study/NCT06242691; https://clinicaltrials.gov/study/NCT07609667" }, { "Gosset drug_id": "69e7743484eb800a451828fe", "Asset": "HLN601", "Developer group": "Hongliang Biopharmaceutical Technology", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Hongliang Biopharmaceutical Technology", "Modality": "Monoclonal Antibodies", "Lead indication": "Advanced malignant solid neoplasms", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e774c084eb800a45182d5c", "Asset": "BA1105", "Developer group": "Boan Biotech", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Boan Biotech", "Modality": "Monoclonal Antibodies", "Lead indication": "Advanced gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e774c784eb800a45182d94", "Asset": "SC0011", "Developer group": "Wuxi Lingfang Biopharmaceutical Technology", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Wuxi Lingfang Biopharmaceutical Technology", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e7753284eb800a4518309d", "Asset": "LY01019", "Developer group": "Boan Biotech", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Boan Biotech", "Modality": "Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e7753884eb800a451830cc", "Asset": "BGC0222", "Developer group": "Gaorui Yaoye", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Gaorui Yaoye", "Modality": "Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69e7787f84eb800a45184a19", "Asset": "ASP8951", "Developer group": "Astellas", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Astellas Pharma", "Modality": "Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69eba7d3082c6575dc1ee5a0", "Asset": "SKB565", "Developer group": "Kelun-Biotech", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "Kelun-Biotech", "Modality": "T-cell Engagers; Bispecific Antibodies", "Lead indication": "Advanced solid tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69faea7d6459d0577866bca1", "Asset": "SMART CAR-T Claudin 18.2", "Developer group": "Gracell Biotechnologies", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Gracell Biotechnologies", "Modality": "CAR-T Cells", "Lead indication": "Gastric/Gastroesophageal Junction Adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69fc541d1e0200d6557a110b", "Asset": "CLDN18.2-CD137", "Developer group": "NovaRock Biotherapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "NovaRock Biotherapeutics", "Modality": "Bispecific Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69fc55361e0200d6557a11f7", "Asset": "EK-005", "Developer group": "Shanghai Enkai Cell Technology", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Shanghai Enkai Cell Technology", "Modality": "CAR-T Cells", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69fc55ab1e0200d6557a1266", "Asset": "GB264", "Developer group": "Genor Biopharma", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Genor Biopharma", "Modality": "Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Pancreatic cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69fc57d71e0200d6557a144b", "Asset": "LNO-A01", "Developer group": "Linno Pharmaceuticals", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Linno Pharmaceuticals", "Modality": "Cytotoxic ADCs", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69fc58881e0200d6557a14f2", "Asset": "JS017", "Developer group": "Junshi", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Junshi Biosciences", "Modality": "Cytotoxic ADCs", "Lead indication": "Gastroesophageal junction adenocarcinoma, unresectable locally advanced or metastatic, CLDN18.2-high (staining intensity ≥2+ in ≥40% of tumor cells)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "69fc5e551e0200d6557a19d4", "Asset": "Claudin18.2 CAR-T", "Developer group": "SiDanSai Biotechnology", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "SiDanSai Biotechnology", "Modality": "CAR-T Cells", "Lead indication": "Advanced Gastric Adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a03ade0868d20e842e746e1", "Asset": "TRO-01", "Developer group": "TriOar", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "TriOar", "Modality": "Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a04aa6295369373bdd0ba69", "Asset": "ATS1002", "Developer group": "AbTis", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "AbTis", "Modality": "Cytotoxic ADCs; Bispecific Antibodies", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0cd737cb42be6b26fed45f", "Asset": "WP-001", "Developer group": "Waypoint Bio", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Waypoint Bio", "Modality": "CAR-T Cells", "Lead indication": "Advanced gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0d2106a0eb349f3bcd31e6", "Asset": "177Lu-DOTA-SNA040", "Developer group": "SmartNuclide", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Active", "Developer / rights": "SmartNuclide", "Modality": "Beta Emitters; Alpha Emitters; Peptides", "Lead indication": "Gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0df52fbdaf83b8ae3c682f", "Asset": "Majiazi", "Developer group": "Chengdu Majiazi Biotechnology", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Chengdu Majiazi Biotechnology", "Modality": "Not recorded", "Lead indication": "Not recorded", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0e5443b20bf2c98f041dba", "Asset": "claudin 18.2 CAR-T", "Developer group": "Immunofoco", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Immunofoco", "Modality": "Gene Addition/Replacement; CAR-T Cells; Gene Silencing; Gene Editing", "Lead indication": "Advanced/metastatic CLDN18.2-positive gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0f7760ff280b7937c43ef1", "Asset": "CLDN18.2 UCAR-T cell injection", "Developer group": "Suzhou Maximum Bio-tech", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Suzhou Maximum Bio-tech", "Modality": "CAR-T Cells", "Lead indication": "CLDN18.2-positive unresectable or metastatic gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0fa974ff280b7937c4ec1a", "Asset": "EMB-15", "Developer group": "Elpiscience", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Elpiscience", "Modality": "Bispecific Antibodies", "Lead indication": "CLDN18.2-positive advanced or metastatic gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0fc3f3a9a35e9bb406e837", "Asset": "CLDN18.2 CAR-iNKT", "Developer group": "Arovella Therapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Arovella Therapeutics", "Modality": "Cell Therapies", "Lead indication": "Advanced or metastatic CLDN18.2-positive gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0fc3f8a9a35e9bb406e838", "Asset": "XNW27011-mAb", "Developer group": "Evopoint Biosciences", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Evopoint Biosciences", "Modality": "Monoclonal Antibodies", "Lead indication": "Locally advanced, unresectable, or metastatic HER2-negative gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0fc3fda9a35e9bb406e83a", "Asset": "single-target CLDN18.2 ADC", "Developer group": "Not recorded", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Not recorded", "Modality": "Cytotoxic ADCs", "Lead indication": "Advanced or metastatic gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0fc403a9a35e9bb406e83c", "Asset": "CLDN18.2 bispecific antibody", "Developer group": "Akeso", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Akeso", "Modality": "Bispecific Antibodies", "Lead indication": "Advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma expressing CLDN18.2", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a0fc45ca9a35e9bb406e872", "Asset": "anti-CLDN18.2/anti-CD3 bispecific antibody", "Developer group": "Accurus Biosciences", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Accurus Biosciences", "Modality": "Bispecific Antibodies", "Lead indication": "Advanced or metastatic CLDN18.2-positive solid tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a18df586de278e693ea0b85", "Asset": "68Ga-NODAGA-SNA014", "Developer group": "SmartNuclide", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "SmartNuclide", "Modality": "Nanobodies (VHH); Beta Emitters; Alpha Emitters", "Lead indication": "CLDN18.2-positive gastric (stomach) adenocarcinoma", "Diagnostic flag": true, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a23873e4aeb5fd87e89aaf5", "Asset": "EBNK-1822H2", "Developer group": "Beijing Biotech", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "Beijing Biotech", "Modality": "CAR-NK Cells; Lymphokine-Activated Killer Cells", "Lead indication": "Gastric adenocarcinoma, unresectable locally advanced or metastatic", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a56dbb74aeb5fd87e91f295", "Asset": "VBC108", "Developer group": "Velavigo Shanghai Pharmaceutical", "Chart phase": "2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Developer / rights": "Velavigo Shanghai Pharmaceutical", "Modality": "Cytotoxic ADCs; Bispecific Antibodies", "Lead indication": "Gastric cancer", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a5ae9a14aeb5fd87e929b5c", "Asset": "IR199", "Developer group": "Huashan Hospital", "Chart phase": "1", "Gosset phase": "1", "Gosset maintenance status": "Stale", "Developer / rights": "Huashan Hospital", "Modality": "Beta Emitters; Alpha Emitters", "Lead indication": "CLDN18.2-positive locally advanced or metastatic gastric adenocarcinoma (including gastroesophageal junction adenocarcinoma)", "Diagnostic flag": true, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a825849d57ea251dff5d968", "Asset": "B901", "Developer group": "Mingji Biopharmaceutical", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Mingji Biopharmaceutical", "Modality": "Cytotoxic ADCs", "Lead indication": "CLDN18.2-positive advanced or metastatic/unresectable gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a8d79fd8172d854c8e6ad2e", "Asset": "arcotatug tavetecan", "Developer group": "Innovent", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Innovent Biologics", "Modality": "Cytotoxic ADCs", "Lead indication": "CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJA), previously treated with ≥2 prior systemic therapies", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a8f93e8a6ee75675c55e150", "Asset": "PM3023", "Developer group": "Pumis Biotechnology", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Pumis Biotechnology", "Modality": "CAR-T Cells", "Lead indication": "Advanced Claudin 18.2–positive malignant solid tumors (including advanced gastric adenocarcinoma and gastroesophageal junction adenocarcinoma)", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a8f96cba6ee75675c55eb5d", "Asset": "[131I]-IR199", "Developer group": "Huashan Hospital", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Huashan Hospital", "Modality": "Beta Emitters; Alpha Emitters", "Lead indication": "Advanced or metastatic Claudin 18.2–positive gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a90db8b806e2463688fe54e", "Asset": "CAR-T cells targeting mesothelin or claudin18.2", "Developer group": "Wuxi People's Hospital", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Wuxi People's Hospital", "Modality": "CAR-T Cells", "Lead indication": "Advanced CLDN18.2-positive gastric or gastro-oesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a918b1ab6914ab2884284fe", "Asset": "TST106", "Developer group": "Transcenta", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Transcenta", "Modality": "Cytotoxic ADCs; Bispecific Antibodies", "Lead indication": "Claudin 18.2-positive gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a918b1eb6914ab288428500", "Asset": "TST198", "Developer group": "Transcenta", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Transcenta", "Modality": "Beta Emitters; Alpha Emitters", "Lead indication": "Claudin 18.2-positive locally advanced or metastatic gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a91a251b6914ab288428c81", "Asset": "duraCAR-T71", "Developer group": "Protheragen", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Protheragen", "Modality": "CAR-T Cells", "Lead indication": "Advanced Claudin 18.2-positive gastric cancer and gastroesophageal junction adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a91a612b6914ab288428da3", "Asset": "SPX-1011", "Developer group": "SPARX THERAPEUTICS", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "SPARX THERAPEUTICS", "Modality": "Cytotoxic ADCs; Monoclonal Antibodies", "Lead indication": "CLDN18.2-positive advanced or refractory solid tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a91a625b6914ab288428dac", "Asset": "SPX-301", "Developer group": "SPARX THERAPEUTICS", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "SPARX THERAPEUTICS", "Modality": "Bispecific Antibodies", "Lead indication": "Gastric adenocarcinoma", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a91e2eeb6914ab28842a002", "Asset": "CLDN18.2 antibody", "Developer group": "NovaRock Biotherapeutics", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "NovaRock Biotherapeutics", "Modality": "Monoclonal Antibodies", "Lead indication": "Advanced gastric adenocarcinoma, including gastroesophageal junction adenocarcinoma, CLDN18.2-positive", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" }, { "Gosset drug_id": "6a9b224e6965e686e32ee7cd", "Asset": "DA-3502", "Developer group": "Dong-A ST", "Chart phase": "Preclinical", "Gosset phase": "Preclinical", "Gosset maintenance status": "Stale", "Developer / rights": "Dong-A ST", "Modality": "Cytotoxic ADCs; Bispecific Antibodies", "Lead indication": "Gastric adenocarcinoma and gastroesophageal junction adenocarcinoma with CLDN18.2-positive and/or HER2-positive tumors", "Diagnostic flag": false, "Individually reviewed": false, "Status / review scope": "Recorded phase; current development status not independently verified in this example.", "Development context": "", "Trial URLs": "" } ]